Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpura
- 25 November 2005
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 132 (1), 66-74
- https://doi.org/10.1111/j.1365-2141.2005.05837.x
Abstract
International audienceIn order to assess the prognostic value of inhibitory anti-ADAMTS13 antibodies in thrombotic thrombocytopenic purpura (TTP), we performed a multicentre prospective study of 33 adult patients with idiopathic acquired TTP. Patients were treated with high-dose plasma infusion and therapeutic plasma exchange. Patients without (group 1, n = 12) and with (group 2, n = 21) detectable inhibitory anti-ADAMTS13 antibodies were compared for clinical presentation, treatment and outcome. Both groups were comparable for clinical presentation. All patients in group 1 achieved a sustained complete remission within a median of 7 d [95% confidence interval (CI), 4-18], which required a median plasma volume of 235 ml/kg (range, 131-1251). In group 2, 17 patients achieved a durable complete remission within a median of 23 d (95% CI, 11-32) (P = 0.001). Median plasma volume was 718 ml/kg (range, 219-3107) (P = 0.02). In group 2, there was a trend for more episodes of flare-up than in group 1 (13 vs. 3, respectively, P = 0.07). Four patients, all from group 2, died (P = not significant). The relapse rate was comparable between both groups. We suggest that TTP with detectable inhibitory anti-ADAMTS13 antibodies displays a worse prognosis, relative to a delayed platelet count recovery, a higher plasma volume requirement to achieve complete remission, and a trend for more frequent episodes of flare-upKeywords
This publication has 31 references indexed in Scilit:
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesBlood, 2005
- Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpuraBlood, 2004
- Measurement of von Willebrand factor cleaving protease (ADAMTS‐13): results of an international collaborative study involving 11 methods testing the same set of coded plasmasJournal of Thrombosis and Haemostasis, 2004
- Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpuraBlood, 2004
- Recent Advances in Thrombotic Thrombocytopenic PurpuraHematology-American Society Hematology Education Program, 2004
- Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpuraBlood, 2003
- Von Willebrand factor–cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpuraBlood, 2002
- Treatment‐free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamideArthritis & Rheumatism, 1994
- Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 1994
- Plasmapheresis in systemic lupus erythematosus. a cautionary noteArthritis & Rheumatism, 1981